News
12-08-2011, 04:10 AM
In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson Cancer Center...
More... (http://www.medicalnewstoday.com/releases/238840.php)
More... (http://www.medicalnewstoday.com/releases/238840.php)